Anti-Inflammatories - Small Molecule Approaches Taking Place April 17-18, 2012 in San Diego

Jan. 25, 2012 - PRLog -- Cambridge Healthtech Institute’s Third Annual Anti-Inflammatories: Small Molecule Approaches will be held April 17-18, 2012 in San Diego as part of the Drug Discovery Chemistry conference.  Early registration discount expires January 27th, register early & save up to $300!

View the final agenda at http://www.drugdiscoverychemistry.com/ifl/

JAK kinase inhibitors will probably be the first new class of oral anti-inflammatories on the market, with the first one likely to receive approval end of 2012. But which JAK or combinations of JAK enzymes is going to prove the best to inhibit in terms of side effects and overall risk benefit profile to patients? How are the other kinase inhibitors aimed at targeting SYK and BTK, targeted for autoimmune disease but with broader potential in diseases such as cancer, progressing?

Program Agenda:

ORAL ANTI-INFLAMMATORY DRUG CANDIDATES (BESIDES KINASE INHIBITORS

KEYNOTE PRESENTATION

Immunology/Inflammation Overview - via Imaging in Vivo
Paul Garside, Ph.D., Professor, Immunology, University of Glasgow

Pre-Clinical and Clinical Profile of the Dual S1P1/S1P5 Modulator BAF312, in Development for the Treatment of Multiple Sclerosis
Barbara Nuesslein-Hildesheim, Ph.D., Director, Autoimmunity, Transplantation & Inflammation Disease Area, Novartis Institutes for BioMedical Research

Discovery and Early Clinical Development of ARRY-502 a CRTh2/DP2 Antagonist for the Treatment of Allergic Inflammation
David Chantry, Ph.D., Senior Director, Cellular and Translational Biology, Array Biopharma

Dissociated Agonist of Gluco-corticoid Receptor: Pre-Clinical and Clinical Development of a Selective Glucocorticoid Anti-Inflammatory
Suvit Thaisrivongs, Ph.D., Vice President, Chemistry, Pfizer

The Role of the Inflammatory Enzyme C2GNT in Diabetic Retinopathy: Journey from Lab to Clinical Application
Rakesh Chibber, Ph.D., Senior Lecturer, Institute of Biomedical and Clinical Science,

JAK AND SYK INHIBITORS FOR INFLAMMATION

Discovery and Development Update on Tofacitinib
Mark Flanagan, Ph.D., Senior Principal Scientist, Worldwide Medicinal Chemistry, Pfizer

Development of JAK inhibitor, AC430, for Inflammation-Related Conditions
Robert C. Armstrong, Ph.D., Executive Director of Pharmacology, Ambit Biosciences Corporation

Discovery of a Potent Syk Kinase Inhibitor R343 as a Treatment for Allergic Asthma
Esteban Masuda, Ph.D., Vice President, Immunology, Rigel Pharmaceuticals

Selection of Safer and More Effective Anti-Inflammatory Kinase Inhibitors Using a Platform of Primary Human Cell Based Disease Models (BioMAP® systems)
Ellen Berg, Ph.D., GM and CSO, BioSeek, LLC

PROBING INFLAMMATION

Discovery and Development of Novel Small Molecule Inhibitors of HDAC and PI3K Isoforms for the Treatment of Immune-Inflammatory Disease
Stephen Shuttleworth, Ph.D., CSO, Karus Therapeutics

Panel Discussion: Stargazing? Progress in Probing Inflammation Early
Moderator: Martin Braddock, Ph.D., Senior Scientist, Global Project Leadership, AstraZeneca R&D

BTK AND OTHER KINASE INHIBITORS FOR INFLAMMATION

Small Molecule BTK Inhibitors: An Update from Pharmacyclics
Wei Chen, Ph.D., Associate Director, Medicinal Chemistry, Pharmacyclics, Inc

Update on Targeting I kKinase for Inflammation
Bill Pitts, Ph.D., Group Leader, Medicinal Chemistry, Bristol Myers Squibb

IkKbeta Inhibitor Program
Erick Young, Ph.D., Senior Research Fellow, Medicinal Chemistry, Boehringer Ingelheim

For more information, or to register today visit http://www.drugdiscoverychemistry.com/ifl/

Register by Friday, January 27th & save up to $300!

# # #

Since 1992, Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations.